KR860000315A - 변형된 탄수화물 잔기를 갖는 항종양성 당단백질의 제조방법 - Google Patents

변형된 탄수화물 잔기를 갖는 항종양성 당단백질의 제조방법 Download PDF

Info

Publication number
KR860000315A
KR860000315A KR1019850004354A KR850004354A KR860000315A KR 860000315 A KR860000315 A KR 860000315A KR 1019850004354 A KR1019850004354 A KR 1019850004354A KR 850004354 A KR850004354 A KR 850004354A KR 860000315 A KR860000315 A KR 860000315A
Authority
KR
South Korea
Prior art keywords
glycoprotein
lysine
chain
starting material
agrostin
Prior art date
Application number
KR1019850004354A
Other languages
English (en)
Other versions
KR930000058B1 (ko
Inventor
잔센 프란쯔 (외 1)
Original Assignee
미쉘 드 아스
소시에떼 아노님 사노피
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR8409703A external-priority patent/FR2566271B1/fr
Priority claimed from FR8502067A external-priority patent/FR2577137B1/fr
Application filed by 미쉘 드 아스, 소시에떼 아노님 사노피 filed Critical 미쉘 드 아스
Publication of KR860000315A publication Critical patent/KR860000315A/ko
Application granted granted Critical
Publication of KR930000058B1 publication Critical patent/KR930000058B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A61K47/6827—Ricin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Botany (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

내용 없음

Description

변형된 탄수화물 잔기를 갖는 항종양성 당단백질의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (7)

  1. 변형시키지 않은 항종양성 당단백질을 과요오드산이온을 사용하여 산화시킴을 특징으로 하는, 카르보히드레이트 잔기를 변형시킨 항종양성 당단백질의 제조방법.
  2. 리보솜을 비활성화시키고 티올기를 임의로 보호한 당단백질 수용액을 빛의 차단하의 0~15℃의 온도에서 0.2~24시간동안 알카리금속 과요오드산염 수용액과 반응시키고, 적당하다면 티올기를 탈보호한후 공지의 방법으로 최종 생성물을 분리함을 특징으로 하는, 리보솜을 비활성화시키고 지연작용을 갖는 당단백질의 제조방법.
  3. 제2항에 있어서, 출발물질로 리신의 A사슬, 겔로닌, GPIR MOM 또는 GPIR 다이안틴 30을 사용하는 방법.
  4. 제2항에 있어서, 출발물질로 다이안틴 32, 아그로스틴 A, 아그로스틴 B, 아그로스틴 C, HCl 또는 아스파라거스 오피시날리스 억제자를 함유하는 물질로부터 선택한 당단백질을 사용하는 방법.
  5. 제2항에 있어서, 사용하는 출발물질이 고유한 리신의 A사슬 또는 고유한 리신의 A사슬의 단편, 또는 리신의 A사슬 또는 유전자형을 알맞게 변형시킨 세포부터 생합성적으로 제조한 그의 단편인 방법.
  6. 제2항에 있어서, 출발물질의 기능화된 리신의 A사슬의 방법.
  7. 제6항에 있어서, 리신의 A사슬이 매틸화 반응에 의해 기능화되는 방법.
    ※ 참고사항 : 최초출원내용에 의하여 공개하는 것임.
KR1019850004354A 1984-06-20 1985-06-19 변형된 탄수화물 잔기를 갖는 항종양성 당단백질의 제조방법 KR930000058B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR8409703A FR2566271B1 (fr) 1984-06-20 1984-06-20 Nouveaux conjugues cytotoxiques utilisables en therapeutique et procede d'obtention
FR84-09703 1984-06-20
FR85-02067 1985-02-13
FR8502067A FR2577137B1 (fr) 1985-02-13 1985-02-13 Glycoproteines antitumorales, modifiees sur leurs motifs glucidiques

Publications (2)

Publication Number Publication Date
KR860000315A true KR860000315A (ko) 1986-01-28
KR930000058B1 KR930000058B1 (ko) 1993-01-06

Family

ID=26224020

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019850004354A KR930000058B1 (ko) 1984-06-20 1985-06-19 변형된 탄수화물 잔기를 갖는 항종양성 당단백질의 제조방법

Country Status (14)

Country Link
EP (1) EP0172045B1 (ko)
JP (1) JPS6112628A (ko)
KR (1) KR930000058B1 (ko)
AT (1) ATE40700T1 (ko)
AU (1) AU593211B2 (ko)
CA (1) CA1248874A (ko)
DE (1) DE3568167D1 (ko)
DK (1) DK166626B1 (ko)
ES (1) ES8605681A1 (ko)
GR (1) GR851497B (ko)
IE (1) IE58514B1 (ko)
IL (1) IL75484A0 (ko)
NZ (1) NZ212439A (ko)
PT (1) PT80662B (ko)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2577135B1 (fr) * 1985-02-13 1989-12-15 Sanofi Sa Immunotoxines a longue duree d'action comportant un constituant glycopeptidique inactivant les ribosomes modifie sur ses motifs polysaccharidiques
IL80973A (en) * 1985-12-20 1992-08-18 Sanofi Sa Modified ribosome-inactivating glycoproteins,their preparation,immunotoxins containing them and pharmaceutical compositions containing such immunotoxins
FR2602682B1 (fr) * 1986-08-12 1988-12-02 Sanofi Sa Immunotoxines a longue duree d'action in vivo comportant une glycoproteine inhibant les ribosomes, modifiee par oxydation des motifs osidiques et formation d'une base de schiff
FR2601679B1 (fr) * 1986-07-15 1990-05-25 Sanofi Sa Immunotoxines, procede de preparation et compositions pharmaceutiques en contenant
US6610299B1 (en) 1989-10-19 2003-08-26 Aventis Pharma Deutschland Gmbh Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
DE4106389A1 (de) * 1991-02-28 1992-09-03 Behringwerke Ag Fusionsproteine zur prodrug-aktivierung, ihre herstellung und verwendung
US6475486B1 (en) 1990-10-18 2002-11-05 Aventis Pharma Deutschland Gmbh Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
US7241595B2 (en) 1989-10-20 2007-07-10 Sanofi-Aventis Pharma Deutschland Gmbh Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
US5250532A (en) * 1991-04-11 1993-10-05 Dowelanco 3,4,N-trisubstituted-4,5-dihydro-1H-pyrazole-1-carboxamides and their use as insecticides
GB9808485D0 (en) * 1998-04-21 1998-06-17 Univ Cambridge Tech Improvements relating to immunotherapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL47372A (en) * 1975-05-27 1979-10-31 Yeda Res & Dev Fab'dimers bound to daunomycin or adriamycin,their preparation and pharmaceutical compositions containing same
FR2437213A1 (fr) * 1978-09-28 1980-04-25 Cm Ind Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation
JPS5616418A (en) * 1979-07-20 1981-02-17 Teijin Ltd Antitumor protein complex and its preparation
JPS5843926A (ja) * 1981-09-08 1983-03-14 Suntory Ltd 選択性制癌剤

Also Published As

Publication number Publication date
GR851497B (ko) 1985-11-25
KR930000058B1 (ko) 1993-01-06
DK277985D0 (da) 1985-06-19
DK277985A (da) 1985-12-21
JPH0582400B2 (ko) 1993-11-18
DE3568167D1 (en) 1989-03-16
EP0172045A1 (fr) 1986-02-19
EP0172045B1 (fr) 1989-02-08
NZ212439A (en) 1989-01-27
CA1248874A (en) 1989-01-17
AU4364685A (en) 1986-01-02
IE851511L (en) 1985-12-20
JPS6112628A (ja) 1986-01-21
ES544337A0 (es) 1986-04-01
ES8605681A1 (es) 1986-04-01
PT80662A (en) 1985-07-01
AU593211B2 (en) 1990-02-08
IL75484A0 (en) 1985-10-31
DK166626B1 (da) 1993-06-21
PT80662B (en) 1986-12-09
IE58514B1 (en) 1993-10-06
ATE40700T1 (de) 1989-02-15

Similar Documents

Publication Publication Date Title
DE59810193D1 (de) Verfahren zur Herstellung von quellbaren, alterungsbeständigen Stärkemaleaten, biologisch abbaubare Stärkemaleate sowie Verwendung
KR860000315A (ko) 변형된 탄수화물 잔기를 갖는 항종양성 당단백질의 제조방법
ATE73850T1 (de) Verfahren zur herstellung von 2-keto-dglukars|ure.
AU4297389A (en) A method for decolouring sulphuric acid derived from acid production processes
PL235019A1 (ko)
ES457482A1 (es) Metodo para la obtencion de inmunoglobulina.
CH609043A5 (en) Process for the preparation of trans- DELTA <2>-prostaglandins
ATE85602T1 (de) Herstellungsverfahren fuer 2-hydroxynaphthol-6carbons|ure.
ZA9610233B (en) Process of preparing an organic acid
DE3476792D1 (en) Process for removing ammonia from a gas containing sulphurous acid anhydride
KR890012930A (ko) 고순도 테트라클로로-1,4-벤조퀴논의 제조방법
AU646047B2 (en) Sulfite overbased products and process
FR2633939B1 (fr) Procede de production d'acide butyrique normal par fermentation a partir d'un substrat sucre en presence d'au moins une souche de l'espece clostridium
KR900701745A (ko) 2-클로로-4-톨루엔술폰산의 제조방법
KR830004206A (ko) 이소류우신의 정제방법
GB1459315A (en) Process for treating sulphide containing materials
ATE79370T1 (de) Verfahren zur herstellung von vizinalen alkandithiolen.
EP0376185A3 (en) Process for purification of 1,2-bis(nicotinamido)propane
KR850006182A (ko) 시스-3,3,5-트리메틸사이클로헥실-D,L-α-(3-피리딘카복시)-페닐아세테이트의 제조방법
GB2018774A (en) Process of preparation of 2- mercaptobenzthiazole
DE3263140D1 (en) Process for making n-acetyl-2,3-dehydroaminocarboxylic-acid esters
KR890006561A (ko) 디알킬 디클로로숙시네이트의 개선된 제조방법
EP0280331A3 (en) Process for recovering sulfur from acid gas
FR2216223A1 (en) Sulphur dioxide removal from effluent gas - using hydrogen sulphide and a catalyst dissolved in a glycol to obtain improved sulphur yield
ATE45139T1 (de) Verfahren zur herstellung von alkoxibuteninen.

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee